In vivo efficacy of dendrimer–methylprednisolone conjugate formulation for the treatment of lung inflammation

Perspective: Dendrimer drugs for infection and inflammation

“…Generation 3 and Generation 4 PAMAM dendrimers have been successfully used for the delivery of steroids to the lung as an additional treatment approach for asthma [70,71]. They were stable to nebulisation and the characteristics of the aerosol were influenced more by nebuliser design than by dendrimer generation.…”

Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

“…Asthma is characterized by airway hyperresponsiveness (AHR), multicellular inflammation, and airway obstruction and is accompanied by intermittent episodes of wheezing and coughing. 2,3 Inhaled corticosteroids provide one of the most effective curative therapies, but this method has severe side effects with long-term use, [4][5][6] such as hypertension, cataracts, osteoporosis in elderly patients, and stunted growth in children. However, inhaled corticosteroids are still required in the systemic administration of glucocorticoids for intractable asthma or asthmatic exacerbation.…”

Preclinical studies of dendrimer prodrugs

“…MP was conjugated to a hydroxylterminal PAMAM dendrimer via an ester bond, and administered to mice, where it was found to have a significant impact on ovalbumin-stimulated lung inflammation by inhalation using a lysine carrier. As expected, the MP--dendrimer conjugate was retained in the lung for a week and exhibited effective anti-inflammatory activity [59]. Kannan's group also reported that an FA-conjugated PAMAM dendrimer was localized at inflamed and Chlamydia-infected paws and genital tracts following its intravenous injection, which suggested that FA plays a critical role as a ligand in targeting inflammatory diseases [60].…”

“…Kaminskas et al and we recently reported a series of dendrimer prodrugs that exhibited effective antitumor activities via alternative administration methods such as inhalation and subcutaneous injection [34,46]. In addition, Kannan's group and several other researchers investigated the application of a variety of other dendrimer prodrugs to the treatment of diseases such as inflammatory disorders [22,[59][60][61][62][63][64]67]. Dendrimers are nanometer-sized unimolecular nanoparticles that are much smaller than other drug carriers such as liposomes, micelles and emulsions, suggesting that they will exhibit better tissue penetration and diffusion properties than any of these other DDS.…”